Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 110

Results For "Risk"

1411 News Found

Jenburkt Wellness launches D2C brand Zixa strong
Healthcare | April 03, 2022

Jenburkt Wellness launches D2C brand Zixa strong

The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially


New data indicate molnupiravir eliminates Covid-19 rapidly
Biotech | April 03, 2022

New data indicate molnupiravir eliminates Covid-19 rapidly

Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10


Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors
Drug Approval | March 30, 2022

Ondexxya approved in Japan for reversal of acute major bleeds in patients on Factor Xa inhibitors

Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding


Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes
Drug Approval | March 29, 2022

Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes

Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults


USFDA clears IND application for an intranasal RSV vaccine
Biotech | March 29, 2022

USFDA clears IND application for an intranasal RSV vaccine

The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers


USFDA approves EUA for second booster dose of Moderna
News | March 29, 2022

USFDA approves EUA for second booster dose of Moderna

50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age


EU approves Evusheld to prevent Covid-19
Drug Approval | March 28, 2022

EU approves Evusheld to prevent Covid-19

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months


Free guide to Colorectal Cancer Screening now available in Hindi
Healthcare | March 28, 2022

Free guide to Colorectal Cancer Screening now available in Hindi

Colorectal Cancer Screening is now translated into multiple languages to help people worldwide understand why, when and how to screen for colorectal cancer


RCSE partner with Rela Hospitals for  advanced surgical course
Hospitals | March 26, 2022

RCSE partner with Rela Hospitals for advanced surgical course

These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training


Evusheld recommended for market authorisation in EU
Biotech | March 25, 2022

Evusheld recommended for market authorisation in EU

Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months